These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35305699)

  • 21. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
    Chibwana MG; Moyo-Gwete T; Kwatra G; Mandolo J; Hermanaus T; Motlou T; Mzindle N; Ayres F; Chaponda M; Tembo G; Mwenechanya P; Mitole N; Jassi C; Kamng'ona R; Afran L; Mzinza D; Mwandumba HC; Gordon SB; Jere K; Madhi S; Moore PL; Heyderman RS; Jambo KC
    BMC Med; 2022 Mar; 20(1):128. PubMed ID: 35346184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
    Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Winckelmann AA; Bollerup S; Mikkelsen LS; Sørensen AL; Feng S; Fahnøe U; Lassauniere R; Fomsgaard A; Ramirez S; Weis N; Bukh J
    EBioMedicine; 2021 Sep; 71():103519. PubMed ID: 34419923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
    Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
    EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.
    Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J
    Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.
    Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP
    Lancet Microbe; 2022 Jan; 3(1):e52-e61. PubMed ID: 34806056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
    Ober Shepherd BL; Scott PT; Hutter JN; Lee C; McCauley MD; Guzman I; Bryant C; McGuire S; Kennedy J; Chen WH; Hajduczki A; Mdluli T; Valencia-Ruiz A; Amare MF; Matyas GR; Rao M; Rolland M; Mascola JR; De Rosa SC; McElrath MJ; Montefiori DC; Serebryannyy L; McDermott AB; Peel SA; Collins ND; Joyce MG; Robb ML; Michael NL; Vasan S; Modjarrad K;
    Lancet Microbe; 2024 Jun; 5(6):e581-e593. PubMed ID: 38761816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
    Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Mikkelsen LS; Fahnøe U; Bollerup S; Winckelmann AA; Schneider UV; Binderup A; Vizgirda G; Sørensen AL; Vinten CN; Dalegaard MI; Ramirez S; Weis N; Bukh J
    EBioMedicine; 2023 Mar; 89():104475. PubMed ID: 36870117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Landau NR; Tada T
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A
    Lancet Infect Dis; 2023 Mar; 23(3):295-306. PubMed ID: 36273491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
    Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
    Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
    Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.